NextGen Comprehensive Technical Assistance for Health Supply Chain and Pharmaceutical Management IDIQ
In January 2024, the United States Agency for International Development (USAID) awarded a ten-year, $2.2 billion Indefinite Delivery Indefinite Quantity (IDIQ) contract called the NextGen Comprehensive Technical Assistance for Health Supply Chain and Pharmaceutical Management (NextGen CompTA) IDIQ. As a subcontractor to Chemonis, Banyan Global will provide gender equality and social inclusion (GESI) integration support and access to finance expertise.
NextGen CompTA is a mechanism within the Next Generation Global Health Supply Chain Suite of Programs. The purpose of NextGen CompTA is to strengthen systems and provide operational support to ensure sustainable access to and appropriate use of safe, effective, quality-assured, affordable health commodities. NextGen CompTA will work to develop the capacity of local systems, institutions, and individuals to sustainably manage supply chains, for both USAID-procured health commodities and those procured through other donor and national/local systems, and to strengthen local pharmaceutical management systems, including quality pharmaceutical services and national regulatory systems. This will include support for governments to shift from supply chain operators and pharmaceutical service providers to stewards for commodity and service availability and security, with heavier reliance on the private sector to provide operational support. The goal of NextGen CompTA is to ensure sustainable access to and appropriate use of safe, effective, quality-assured, affordable health commodities. NextGen CompTA has the following three objectives:
- Local supply chain systems strengthened to ensure a reliable, sustainable supply of quality health commodities, through public and private sector channels, beyond donor assistance
- Availability of quality-assured, essential health commodities increased, through improved supply chain performance
- Pharmaceutical management systems sustainably strengthened, including quality pharmaceutical services and functional regulatory systems